Using Central IRBs for Multicenter Clinical Trials in the United States

• Kathryn E. Flynn,

  Affiliations Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America

  ⨯
• Cynthia L. Hahn,

  Affiliation Office of Research Compliance, Feinstein Institute for Medical Research, North Shore-Long Island Health System, Manhasset, New York, United States of America

  ⨯
• Judith M. Kramer,

  Affiliations Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America

  ⨯
• Devon K. Check,

  Affiliation Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, United States of America

  ⨯
• Carrie B. Dombeck,

  Affiliation Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, United States of America

  ⨯
• Soo Bang,

  Affiliation Celgene Corporation, Summit, New Jersey, United States of America

  ⨯
• Jane Perlmutter,

  Affiliation Gemini Group, Ann Arbor, Michigan, United States of America

  ⨯
• Felix A. Khin-Maung-Gyi,

  Affiliation Chesapeake IRB, Columbia, Maryland, United States of America

  ⨯
• Kevin P. Weinfurt

  * E-mail: kevin.weinfurt@duke.edu

  Affiliations Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, United States of America

  ⨯